About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
COMPANY NEWS
Company
News
Alembic Pharmaceuticals Ltd.
Change Company
BSE Code
533573
ISIN Demat
INE901L01018
Book Value
269.55
NSE Code
APLLTD
Dividend Yield %
1.16
Market Cap
185909.40
P/E
43.19
EPS
21.90
Face Value
2
1 Week
1 Month
3 Months
6 Months
1 Year
09-Sep-2025
Alembic Pharmaceuticals gets USFDA’s final approv...
29-Aug-2025
Alembic Pharmaceuticals informs about analyst mee...
19-Aug-2025
Alembic Pharmaceuticals gets USFDA’s final approv...
19-Aug-2025
Alembic Pharmaceuticals rises on getting USFDA’s ...
18-Aug-2025
Alembic Pharmaceuticals rises on getting USFDA’s ...
16-Aug-2025
Alembic Pharmaceuticals gets USFDA’s final approv...
05-Aug-2025
Alembic Pharmaceuticals reports 15% rise in Q1 co...
05-Aug-2025
Alembic Pharmaceuticals informs about investor pr...
05-Aug-2025
Alembic Pharmaceuticals informs about outcome of ...
05-Aug-2025
Alembic Pharmaceuticals informs about press relea...
26-Jul-2025
Alembic Pharmaceuticals gets USFDA’s final approv...
26-Jul-2025
Alembic Pharmaceuticals submits press release
03-Jul-2025
Alembic Pharmaceuticals’ arm to acquire Utility T...
03-Jul-2025
Alembic Pharmaceuticals informs about disclosure
03-Jul-2025
Alembic Pharmaceuticals gains as its arm set to a...
Page
1
of
3
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
|
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
|
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
|
Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.